Spero Therapeutics - SPRO Stock Forecast, Price & News

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SPRO shares. Cantor Fitzgerald dropped their target price on shares of Spero Therapeutics from $27.00 to $5.00 in a research report on Tuesday, May 17th. Berenberg Bank cut Spero Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, May 20th. Cowen downgraded Spero Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 4th. Finally, HC Wainwright dropped their price target on Spero Therapeutics from $37.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, May 23rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.33.

Spero Therapeutics Stock Performance

NASDAQ:SPRO traded up $0.10 during trading on Monday, reaching $0.90. The company's stock had a trading volume of 2,611 shares, compared to its average volume of 420,720. The business's fifty day moving average price is $0.89 and its 200-day moving average price is $4.87. Spero Therapeutics has a twelve month low of $0.68 and a twelve month high of $19.87. The firm has a market cap of $29.70 million, a price-to-earnings ratio of -0.25 and a beta of 1.95.

Spero Therapeutics (NASDAQ:SPRO - Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.14). Spero Therapeutics had a negative return on equity of 116.93% and a negative net margin of 792.03%. The company had revenue of $2.07 million for the quarter, compared to analysts' expectations of $2.85 million. During the same period in the prior year, the business earned ($0.66) EPS. As a group, sell-side analysts forecast that Spero Therapeutics will post -3.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors have recently bought and sold shares of SPRO. Vanguard Group Inc. boosted its holdings in Spero Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,373,928 shares of the company's stock valued at $11,953,000 after purchasing an additional 22,550 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Spero Therapeutics by 4.8% in the first quarter. Rock Springs Capital Management LP now owns 990,913 shares of the company's stock valued at $8,621,000 after buying an additional 45,600 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Spero Therapeutics by 9.6% during the first quarter. Dimensional Fund Advisors LP now owns 406,946 shares of the company's stock worth $3,540,000 after acquiring an additional 35,724 shares during the period. OUP Management Co. LLC purchased a new position in Spero Therapeutics in the fourth quarter worth $3,988,000. Finally, Royal Bank of Canada lifted its holdings in Spero Therapeutics by 7.4% in the first quarter. Royal Bank of Canada now owns 196,097 shares of the company's stock valued at $1,706,000 after acquiring an additional 13,502 shares during the period. 69.36% of the stock is owned by institutional investors and hedge funds.